Literature DB >> 19446359

Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer.

Ying Xie1, Nevins W Todd, Zhenqiu Liu, Min Zhan, Hongbin Fang, Hong Peng, Mohammed Alattar, Janaki Deepak, Sanford A Stass, Feng Jiang.   

Abstract

UNLABELLED: Analysis of molecular genetic markers in biological fluids has been proposed as a useful tool for cancer diagnosis. MicroRNAs (miRNAs) are small regulatory RNAs that are frequently dysregulated in lung cancer and have shown promise as tissue-based markers for its prognostication. The aim of this study was to determine whether aberrant miRNA expression can be used as a marker in sputum specimen for the diagnosis of non-small cell lung cancer (NSCLC). EXPERIMENTAL
DESIGN: expressions of mature miRNAs, mir-21 and mir-155, were examined by real-time reverse transcription polymerase chain reaction (RT-PCR) and normalized to that of control miRNA, U6B, in sputum of 23 patients with NSCLC and 17 cancer-free subjects. The data was compared with conventional sputum cytology for the diagnosis of lung cancer. All endogenous miRNAs were present in sputum in a remarkably stable form and sensitively and specifically detected by real-time RT-PCR. Mir-21 expression in the sputum specimens was significantly higher in cancer patients (76.32+/-9.79) than cancer-free individuals (62.24+/-3.82) (P<0.0001). Furthermore, overexpression of mir-21 showed highly discriminative receiver-operator characteristic (ROC) curve profile, clearly distinguishing cancer patients from cancer-free subjects with areas under the ROC curve at 0.902+/-0.054. Detection of mir-21 expression produced 69.66% sensitivity and 100.00% specificity in diagnosis of lung cancer, as compared with 47.82% sensitivity and 100.00% specificity by sputum cytology. The measurement of altered miRNA expression in sputum could be a useful noninvasive approach for the diagnosis of lung cancer. Copyright 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19446359      PMCID: PMC2846426          DOI: 10.1016/j.lungcan.2009.04.004

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  21 in total

Review 1.  Sputum examination for early detection of lung cancer.

Authors:  F B J M Thunnissen
Journal:  J Clin Pathol       Date:  2003-11       Impact factor: 3.411

Review 2.  Focus on lung cancer.

Authors:  John D Minna; Jack A Roth; Adi F Gazdar
Journal:  Cancer Cell       Date:  2002-02       Impact factor: 31.743

Review 3.  Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology.

Authors:  F R Hirsch; W A Franklin; A F Gazdar; P A Bunn
Journal:  Clin Cancer Res       Date:  2001-01       Impact factor: 12.531

4.  Development of carcinoma of the lung as reflected in exfoliated cells.

Authors:  G Saccomanno; V E Archer; O Auerbach; R P Saunders; L M Brennan
Journal:  Cancer       Date:  1974-01       Impact factor: 6.860

5.  MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells.

Authors:  Jennifer A Chan; Anna M Krichevsky; Kenneth S Kosik
Journal:  Cancer Res       Date:  2005-07-15       Impact factor: 12.701

Review 6.  MicroRNAs and lung cancer: new oncogenes and tumor suppressors, new prognostic factors and potential therapeutic targets.

Authors:  Cécile Ortholan; Marie-Pierre Puissegur; Marius Ilie; Pascal Barbry; Bernard Mari; Paul Hofman
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

7.  Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Memorial Sloan-Kettering study.

Authors:  B J Flehinger; M R Melamed; M B Zaman; R T Heelan; W B Perchick; N Martini
Journal:  Am Rev Respir Dis       Date:  1984-10

8.  Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival.

Authors:  Junichi Takamizawa; Hiroyuki Konishi; Kiyoshi Yanagisawa; Shuta Tomida; Hirotaka Osada; Hideki Endoh; Tomoko Harano; Yasushi Yatabe; Masato Nagino; Yuji Nimura; Tetsuya Mitsudomi; Takashi Takahashi
Journal:  Cancer Res       Date:  2004-06-01       Impact factor: 12.701

Review 9.  Noninvasive staging of non-small cell lung cancer: a review of the current evidence.

Authors:  Eric M Toloza; Linda Harpole; Douglas C McCrory
Journal:  Chest       Date:  2003-01       Impact factor: 9.410

10.  Real-time quantification of microRNAs by stem-loop RT-PCR.

Authors:  Caifu Chen; Dana A Ridzon; Adam J Broomer; Zhaohui Zhou; Danny H Lee; Julie T Nguyen; Maura Barbisin; Nan Lan Xu; Vikram R Mahuvakar; Mark R Andersen; Kai Qin Lao; Kenneth J Livak; Karl J Guegler
Journal:  Nucleic Acids Res       Date:  2005-11-27       Impact factor: 16.971

View more
  142 in total

1.  High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer.

Authors:  Xiao-Guang Liu; Wang-Yu Zhu; Yan-Yan Huang; Li-Na Ma; Shi-Quan Zhou; Ye-Kai Wang; Fang Zeng; Ji-Hang Zhou; Yong-Kui Zhang
Journal:  Med Oncol       Date:  2011-04-24       Impact factor: 3.064

Review 2.  Causes and consequences of microRNA dysregulation.

Authors:  Marilena V Iorio; Carlo M Croce
Journal:  Cancer J       Date:  2012 May-Jun       Impact factor: 3.360

Review 3.  The roles of microRNAs on tuberculosis infection: meaning or myth?

Authors:  Harapan Harapan; Fitra Fitra; Ichsan Ichsan; Mulyadi Mulyadi; Paolo Miotto; Nabeeh A Hasan; Marta Calado; Daniela M Cirillo
Journal:  Tuberculosis (Edinb)       Date:  2013-08-15       Impact factor: 3.131

Review 4.  Involvement of microRNAs in lung cancer biology and therapy.

Authors:  Xi Liu; Lorenzo F Sempere; Yongli Guo; Murray Korc; Sakari Kauppinen; Sarah J Freemantle; Ethan Dmitrovsky
Journal:  Transl Res       Date:  2011-02-04       Impact factor: 7.012

5.  Strengths and limitations of laboratory procedures for microRNA detection.

Authors:  Jill Koshiol; Ena Wang; Yingdong Zhao; Francesco Marincola; Maria Teresa Landi
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-03-23       Impact factor: 4.254

6.  The detection of chromosomal aneusomy by fluorescence in situ hybridization in sputum predicts lung cancer incidence.

Authors:  Marileila Varella-Garcia; Aline P Schulte; Holly J Wolf; William J Feser; Chan Zeng; Sarah Braudrick; Xiang Yin; Fred R Hirsch; Timothy C Kennedy; Robert L Keith; Anna E Barón; Steven A Belinsky; York E Miller; Tim Byers; Wilbur A Franklin
Journal:  Cancer Prev Res (Phila)       Date:  2010-03-23

Review 7.  Cancer epigenetics: above and beyond.

Authors:  Mariana Brait; David Sidransky
Journal:  Toxicol Mech Methods       Date:  2011-05       Impact factor: 2.987

Review 8.  Overview upon miR-21 in lung cancer: focus on NSCLC.

Authors:  Cecilia Bica-Pop; Roxana Cojocneanu-Petric; Lorand Magdo; Lajos Raduly; Diana Gulei; Ioana Berindan-Neagoe
Journal:  Cell Mol Life Sci       Date:  2018-07-20       Impact factor: 9.261

9.  Digital PCR quantification of miRNAs in sputum for diagnosis of lung cancer.

Authors:  Ning Li; Jie Ma; Maria A Guarnera; HongBin Fang; Ling Cai; Feng Jiang
Journal:  J Cancer Res Clin Oncol       Date:  2013-11-27       Impact factor: 4.553

10.  microRNA-21 promotes cardiac fibrosis and development of heart failure with preserved left ventricular ejection fraction by up-regulating Bcl-2.

Authors:  Shuguang Dong; Wenhan Ma; Bohan Hao; Fen Hu; Lianhua Yan; Xiaofei Yan; Ya Wang; Zhijian Chen; Zhaohui Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.